Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ONO-2020 in Healthy Participants
NCT05507515Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ONO-2020 in Alzheimer's disease (AD) (5 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Events at Day 21, Vital Signs (Blood Pressure) at Day 21 and 7 more. Started Jul 2022; status: completed.
02
Drugs
ONO-2020
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05507515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507515.